© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Society of Hematologic Oncology
Tweets from Society of Hematologic Oncology
Latest from Society of Hematologic Oncology
Targeted Oncology Welcomes the Society of Hematologic Oncology to Its Strategic Alliance Partnership Program
January 08, 2020
Targeted Oncology, a multimedia resource that offers content and expert opinions on standard and emerging treatments in the oncology field, announces the addition of the Society of Hematologic Oncology to its Strategic Alliance Partnership program.
New Approaches to Increase Failure-Free Survival in Follicular Lymphoma
September 25, 2015
Failure-free survival (FFS) for patients with follicular lymphoma has had a lack of improvement, fueling interest in new treatment strategies that may offer promise for better outcomes.
Ibrutinib Shows Efficacy for the Treatment of Untreated and Relapsed/Refractory CLL
September 24, 2015
Single-agent ibrutinib (Imbruvica) data showed durable responses in patients with untreated or relapsed/refractory chronic lymphocytic leukemia (CLL).
Novel Therapies Show Promise in Mantle Cell Lymphoma
September 24, 2015
New combination strategies are required for heterogeneity of mantle cell lymphoma (MCL), in order to improve outcomes.
Immune Checkpoint Inhibitors in Lymphoma Spark Enthusiasm and Questions
September 24, 2015
Clinical evaluation suggests a role for immune checkpoint inhibition in the treatment of patients with lymphomas, but early success has also raised many questions.